PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Cachexia

Drugs in development · updated 30 October 2026

Cachexia: drugs in development

As of 30 October 2026 there are 11 active clinical trials (recruiting or ongoing, phases I–III) on 9 drugs for cachexia. 8 are experimental, that is not yet approved in the United States.

11Active trials
8Experimental drugs
3Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
PonsegromabII–III2NCT06989437
RilogrotugAV-380II–III2NCT07888075
VisugromabII–III1NCT07112196
ASCA101II1NCT07168226
DS010I–II1NCT07530666
TCMCB07II1NCT06937177
GB18I1NCT07519564
GFS202AI1NCT06898255

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
OlanzapineWeltruza®, Zyprexa Relprevv®II1NCT05705492

Sorted by most advanced phase and number of active trials.

All 9 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D002100 “Cachexia”.

ItalianoFrançaisDeutsch